U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Protein Type ENZYME
Protein Sub Type SERINE/THREONINE-PROTEIN KINASE
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
U7FKT8J0J3
Record Status Validated (UNII)
Record Version
Name Type Language
SERINE/THREONINE-PROTEIN KINASE B-RAF V600E
Common Name English
BRAF V600E
Common Name English
Code System Code Type Description
UNIPROT
P15056 PRIMARY
FDA UNII
U7FKT8J0J3 PRIMARY
Subunit 0

Related Record Type Details
INHIBITOR -> TARGET
In contrast to approved therapies targeting Class I V600E BRAF mutant tumors, KIN-2787 was active across all classes of BRAF-altered melanoma cells.
INHIBITOR -> TARGET
IC50
49.2 NANOMOLAR [46.2 to 52.2] (average)
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
8.2 [6.7 to 9.7] (average)
INHIBITOR -> TARGET
INHIBITOR -> TARGET
IC50
5.8 NANOMOLAR (average)
INHIBITOR -> TARGET
IC50
0.35 NANOMOLAR (average)
RADIOLIGAND->TARGET
A serine/threonine kinase PET imaging agent for the melanomas mainly in the specific expression of the BRAFV600E mutation.
INHIBITOR -> TARGET
INHIBITOR -> TARGET
An ATP competitive inhibitor. Binding assay
COMPETITIVE INHIBITOR
IC50
0.7 NANOMOLAR (average)
WEAK INHIBITOR->TARGET
IC50
495 NANOMOLAR [378 to 612] (average)
INHIBITOR -> TARGET
INHIBITOR -> TARGET
PRECLINICAL
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
ESTIMATED 84300 Da (average)